Cibus Q4 2024 net loss $25.8M; cash $14.4M; reviews strategic alternatives

Cibus, Inc.

Q4 2024 net loss $25.8M vs $277.2M in Q4 2023 (prior-year includes $249.4M goodwill impairment); EPS -$0.87 vs -$12.59.
Cash $14.4M at Dec 31; after Jan 2025 $21.4M net offering, expects runway into late Q3 2025.
Board, with advisor, evaluating full range of strategic alternatives to maximize shareholder value.
Business progress: EU Trilogue advanced; CA Rice Commission approved gene-edited Rice field trial; four Rice seed customer agreements.
Cost-saving initiatives targeting $10M annualized run-rate, ~20% monthly cash use reduction; facility consolidation on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.